Skip to main content

Table 4 Clinical outcomes according to the use of RAAS blockers

From: Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19

Clinical outcome Antihypertensive treatment
(n = 1,044)
ACEI/ARB
(n = 782)
Non-ACEI/ARB
(n = 262)
Unadjusted Age, sex-adjusted Multivariable adjusted
OR (95 % CI) P-value OR (95 % CI) P-value OR (95 % CI) P-value
Hospitalization 540 (51.7) 389 (49.7) 151 (57.6) 1.05 (0.83–1.33) 0.691 1.13 (0.89–1.45) 0.320 1.16 (0.90–1.49) 0.263
Oxygen requirement 142 (13.6) 97 (12.4) 45 (17.2) 0.87 (0.61–1.24) 0.445 0.96 (0.67–1.37) 0.802 0.96 (0.67–1.38) 0.813
Severe outcome 76 (7.3) 49 (6.3) 27 (10.3) 0.58 (0.36–0.95) 0.031 0.66 (0.40–1.09) 0.104 0.68 (0.41–1.15) 0.150
   ICU admission 33 (3.2) 20 (2.6) 13 (5.0) 0.57 (0.30–1.09) 0.084 0.60 (0.31–1.16) 0.127 0.61 (0.32–1.18) 0.139
   Ventilator care 21 (2.0) 12 (1.5) 9 (3.4) 0.47 (0.21–1.05) 0.059 0.51 (0.23–1.14) 0.101 0.48 (0.21–1.08) 0.076
   Death 54 (5.2) 35 (4.5) 19 (7.3) 0.69 (0.41–1.16) 0.161 0.78 (0.45–1.33) 0.358 0.75 (0.43–1.30) 0.302
  1. Data are presented as number (%) unless otherwise specified
  2. RAAS renin-angiotensin-aldosterone-system, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, ICU intensive care unit, OR odds ratios, CI confidence intervals